The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Patients with moderate to severe psoriasis treated with methotrexate (MTX) plus tumor necrosis factor (TNF), interleukin (IL)-17 inhibitors, or IL-23 inhibitors experienced a comparable risk of ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

Early evidence indicates that biologic therapy is effective treatment for not only plaque psoriasis but also erythrodermic and generalized pustular psoriasis. After conducting a literature review of ...

This transcript has been edited for clarity. Steven R. Feldman, MD: Welcome to Medscape InDiscussion on psoriasis. I'm your host, Dr Steve Feldman. Today, we'll be discussing biologic therapy options ...

Following COVID-19–related lockdown measures, preferences for the use of biologics among Japanese patients with psoriasis addressed administration route, visits, and risk of serious infections ...

A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...

DAKOTA DUNES | A woman sits in her hair stylist's chair and brushes her long auburn locks back to reveal red, scaly patches on her neck. Embarrassed, she visits her doctor and is prescribed Humira.